Nucleoside analog monotherapy for prophylaxis in Hepatitis B liver transplant patients is safe and efficacious.

Background: Combination therapy with HBIG and NAs has reduced HBV recurrence post LT. Despite its efficacy, costs of HBIG remain prohibitive. With high-potency NAs, HBIG's use has been questioned.